Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 16/20 | 1.00 |
| ▸ | SRC | P12931 | 9/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 8/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 8/20 | 1.00 |
| ▸ | PRKCA | P17252 | 6/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 4/20 | 1.00 |
| ▸ | BCR | P11274 | 14/20 | 0.98 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.64 |
| ▸ | PRKCG | P05129 | 1/20 | 0.64 |
| ▸ | PRKCB | P05771 | 1/20 | 0.64 |
| ▸ | PRKCH | P24723 | 1/20 | 0.64 |
| ▸ | PRKCI | P41743 | 1/20 | 0.64 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.64 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.64 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.64 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.64 |
| ▸ | JAK2 | O60674 | 2/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.62 |
| ▸ | ABL2 | P42684 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14705763 | 0.87 | ABL1 (0.77) | ABL1SRCPDGFRBPDGFRAPRKCA | |
| SCHEMBL4901346 | 0.85 | ABL1 (0.74) | ABL1SRCPDGFRBPDGFRAPRKCA | |
| SCHEMBL7468958 | 0.83 | ABL1 (0.76) | ABL1SRCPDGFRBPDGFRAPRKCA | |
| SCHEMBL14224137 | 0.80 | ABL1 (0.66) | ABL1SRCPDGFRBPDGFRAPRKCA | |
| SCHEMBL4894465 | 0.79 | ABL1 (0.73) | ABL1SRCPDGFRBPDGFRAPRKCA | |
| SCHEMBL1522 | 0.79 | ABL1 (1.00) | ABL1SRCPDGFRBPDGFRAPRKCA | |
| Cyclohexane SCHEMBL5776701 | 0.79 | ABL1 (0.76) | ABL1SRCPDGFRBPDGFRAPRKCA | |
| SCHEMBL7465138 | 0.79 | ABL1 (0.80) | ABL1SRCPDGFRBPDGFRAPRKCA | |
| SCHEMBL14196037 | 0.78 | ABL1 (0.64) | ABL1SRCPDGFRBPDGFRAPRKCA | |
| SCHEMBL9197 | 0.78 | ABL1 (1.00) | ABL1SRCPDGFRBPDGFRAPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112110906-A | Novel use of conjugates | 中山万汉制药有限公司 | 2020-12-22 | — | — | CN | claimed |
| CN-112079821-A | Conjugate formed by orlistat and phenylaminopyrimidine compound and preparation method and application thereof | 中山万汉制药有限公司 | 2020-12-15 | — | — | CN | claimed |
| CN-112043708-A | Anti-hepatitis B use of conjugates | 中山万汉制药有限公司 | 2020-12-08 | — | — | CN | claimed |
| WO-2005065074-A2 | PROTECTION OF TISSUES AND CELLS FROM CYTOTOXIC EFFECTS OF IONIZING RADIATION BY ABL INHIBITORS | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2005-07-21 | — | — | WO | claimed |
| EP-0564409-B1 | Pyrimidin derivatives and process for their preparation | NOVARTIS AG (CH) | 2000-01-19 | — | — | EP | claimed |
| US-5521184-A | ANTITUMOR AGENTS; imatinib mesylate | CIBA-GEIGY CORPORATION (US) | 1996-05-28 | — | — | US | claimed |
| EP-0564409-A1 | Pyrimidin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-10-06 | — | — | EP | claimed |
| CN-112110906-A | Novel use of conjugates | 中山万汉制药有限公司 | 2020-12-22 | — | — | CN | disclosed |
| CN-112079821-A | Conjugate formed by orlistat and phenylaminopyrimidine compound and preparation method and application thereof | 中山万汉制药有限公司 | 2020-12-15 | — | — | CN | disclosed |
| CN-112043708-A | Anti-hepatitis B use of conjugates | 中山万汉制药有限公司 | 2020-12-08 | — | — | CN | disclosed |
| US-20130338168-A1 | Combinations of JAK Inhibitors | NOVARTIS AG (CH) | 2013-12-19 | — | — | US | disclosed |
| US-20100280003-A1 | COMBINATIONS OF JAK INHIBITORS | COOKE NIGEL GRAHAM | 2010-11-04 | — | — | US | disclosed |
| US-20090156602-A1 | Organic Compounds | COOKE NIGEL GRAHAM | 2009-06-18 | — | — | US | disclosed |
| EP-1539041-A1 | DEVICES DELIVERING THERAPEUTIC AGENTS AND METHODS REGARDING THE SAME | Avantec Vascular Corporation (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2005051229-A2 | DEVICES DELIVERING THERAPEUTIC AGENTS AND METHODS REGARDING THE SAME | AVANTEC VASCULAR CORPORATION (US) | 2005-06-09 | — | — | WO | disclosed |
| US-20050125054-A1 | Devices delivering therapeutic agents and methods regarding the same | AVANTEC VASCULAR CORPORATION (US) | 2005-06-09 | — | — | US | disclosed |
| WO-2004010900-A1 | DEVICES DELIVERING THERAPEUTIC AGENTS AND METHODS REGARDING THE SAME | AVANTEC VASCULAR CORPORATION (US) | 2004-02-05 | — | — | WO | disclosed |
| EP-0564409-B1 | Pyrimidin derivatives and process for their preparation | NOVARTIS AG (CH) | 2000-01-19 | — | — | EP | disclosed |
| US-5521184-A | ANTITUMOR AGENTS; imatinib mesylate | CIBA-GEIGY CORPORATION (US) | 1996-05-28 | — | — | US | disclosed |
| EP-0564409-A1 | Pyrimidin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280003-A1 | COMBINATIONS OF JAK INHIBITORS | JAK2, JAK3, JAK1 | ABL1 5/4885SRC 9/4885PDGFRB 40/4885 |
| US-20130338168-A1 | Combinations of JAK Inhibitors | JAK2, JAK3, JAK1 | ABL1 5/4885SRC 9/4885PDGFRB 40/4885 |
| US-20090156602-A1 | Organic Compounds | BTK, JAK2, JAK3 | ABL1 4/4885SRC 8/4885PDGFRB 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.